Home › Trials › NCT04433442

Assessing the safety and symptom changes of Risankizumab in adults with moderate to severe psoriasis and psoriatic arthritis

Post-Marketing Surveillance to Evaluate the Safety and Effectiveness of Risankizumab (Skyrizi) in Adult Moderate to Severe Plaque Psoriasis and Psoriatic Arthritis Patients

AbbVie · NCT04433442

This study is testing if Risankizumab can safely help adults with moderate to severe psoriasis and psoriatic arthritis feel better.

Quick facts

Study typeObservational
Enrollment3000 (estimated)
Ages19 Years and up
SexAll
SponsorAbbVie (industry)
Drugs / interventionsrisankizumab
Locations63 sites (Busan, Busan Gwang Yeogsi and 62 other locations)
Trial IDNCT04433442 on ClinicalTrials.gov

What this trial studies

This study evaluates the safety and effectiveness of Risankizumab, an approved treatment for moderate to severe plaque psoriasis and psoriatic arthritis, in adult participants. Approximately 3000 adults who have been prescribed Risankizumab will be enrolled across multiple sites in Korea. The study aims to assess changes in disease symptoms and monitor any adverse effects associated with the treatment. Participants will receive the medication via prefilled syringes as part of their treatment regimen.

Who should consider this trial

Good fit: Ideal candidates include adults with moderate to severe plaque psoriasis or psoriatic arthritis who are suitable for treatment with Risankizumab.

Not a fit: Patients who have contraindications to Risankizumab as listed on the approved local label will not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide valuable insights into the safety and efficacy of Risankizumab for patients suffering from these chronic conditions.

How similar studies have performed: Other studies have shown positive outcomes with Risankizumab in treating psoriasis and psoriatic arthritis, indicating a promising approach.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Suitable for the treatment with risankizumab according to the approved local label.
* Voluntarily agree to participate in this study and sign informed consent.

Exclusion Criteria:

- Contraindications to risankizumab as listed on the approved local label.

Where this trial is running

Busan, Busan Gwang Yeogsi and 62 other locations

+13 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Psoriasis, Psoriatic Arthritis, Plaque Psoriasis, Risankizumab, Skyrizi, Prefilled syringe

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.